Last Modified: July 25, 2014
Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals.
Release date: July 24, 2014
Expiration date: July 24, 2015
Estimated time to complete: 1.25 hours
Activity URL: www.oncolink.org/resources/article.cfm?aid=7068&id=7068&c=412
This activity has been designed to meet the educational needs of oncology nurses and nurse practitioners involved in the care of patients with metastatic colorectal cancer (mCRC).
More than 140,000 adults in the US will be diagnosed with CRC this year. At the time of diagnosis, a quarter of these patients will have metastases, and 50% to 60% of the remainder will develop metastasis during the course of treatment.
A number of drugs have demonstrated activity in mCRC. However, adherence to guideline-recommended treatment for mCRC is suboptimal, and many patients receive treatment outside of evidence-based, best-practice standards. Because adherence to guidelines has been found to improve outcomes in mCRC, it is imperative that all healthcare professionals improve their ability to adhere to evidence-based practices for the management of this condition.
Oncology nursing professionals play a critical role in the management of cancers, including mCRC. Given the major role of oncology nurses and nurse practitioners as well as the challenges they face while involved in CRC management, it is critical that these individuals are knowledgeable and competent in all aspects of therapy and management. This will allow them to improve their abilities and role within the healthcare team managing these patients.
Carolyn Grande, CRNP, AOCNP
Nurse Practitioner, Abramson Cancer Center
Hospital of the University of Pennsylvania
Upon completion of this educational activity, learners should be better able to:
American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
American Academy of CME, Inc. designates this educational activity for 1.25 contact hours (including 1.25 pharmacotherapeutic contact hours).
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Carolyn Grande, CRNP, AOCNP, has received grant/research support as a sub-investigator from Bayer HealthCare Pharmaceuticals, Exelixis, Novartis Pharmaceuticals, Roche Pharmaceuticals, and Eisai Pharmaceuticals.
Angela Laffan, RN, ANP, AOCN, Nurse Practitioner, GI Oncology, Stanford Hospital. Ms. Laffan is a shareholder in Exact Sciences.
Linda Mai Penwarden, RN, MN, AOCN, Oncology Clinical Nurse Specialist, St. Luke's Mountain States Tumor Institute. Ms. Penwarden is on the advisory board for Amgen Oncology; an employee of St. Luke's Mountain States Tumor Institute; the promotional speaker's bureau for Eisai Pharmaceuticals; and has a contract with the American Society of Clinical Oncology for their Quality Oncology Practice Initiative Certification Program.
Emily Petito, MSN, CRNP, Nurse Practitioner, Division of Medical Oncology, Johns Hopkins University. Ms. Petito has no relevant financial relationships to disclose.
Fredrica "Ricky" Preston, RNC, NP, AOCN, Nurse Practitioner, Medical Oncology, MGH North Shore Cancer Center. Ms. Preston has no relevant financial relationships to disclose.
Carole Viele, RN, MS, CNS, Associate Clinical Professor, Department of Physiological Nursing University of California, San Francisco. Ms. Viele is on the advisory board for Novartis and the promotional speaker's bureaus for Novartis, Merck, and Celgene.
John JD Juchniewicz, MCIS, CCMEP, Paul J. Miniter, MS, and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner; American Academy of CME: No relevant financial relationships with any commercial interests.
Elizabeth Paczolt, MD, Mindy Aratow, Pat McCollum; Excellence in Medical Education: No relevant financial relationships with any commercial interests.
This activity will not review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, Excellence in Medical Education, or American Nurses Credentialing Council's Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please complete the post assessment (achieving a passing score of 70% or higher) and program evaluation. If asked, the activity ID is 13XM11W. Your certificate can be printed immediately.
Participants will need to have QuickTime, Windows Media Player, or VLC to view the program.
For any questions, please contact: CEServices@academycme.org
Copyright © 2014. This CNE-certified activity is held as copyrighted © by American Academy of CME and Excellence in Medical Education. Through this notice, the Academy and Excellence in Medical Education grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Jan 20, 2012 - For patients with metastatic colorectal cancer that has progressed after standard therapies, treatment with regorafenib significantly improves overall survival and progression-free survival compared with placebo, according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 19 to 21 in San Francisco.